Involvement of central immunity in uncomplicated diverticular disease

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 1, 2009, Pages 108-115

  Cianci, Rossella ^a   Iacopini, Federico ^a   Petruzziello, Lucio ^a   Cammarota, Giovanni ^a   Pandolfi, Franco ^a   Costamagna, Guido ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alpha beta7 integrin; CD103; Immunity; Rifaximin; Uncomplicated diverticular disease

Indexed keywords

CD103 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; MONOCLONAL ANTIBODY; RIFAXIMIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLON DIVERTICULOSIS; COLON MUCOSA; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNITY; LYMPHOCYTE SUBPOPULATION; MALE; MUCOSAL IMMUNITY; PATIENT COMPLIANCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SIGMOID; TRANSVERSE COLON; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, CD8; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLON, SIGMOID; COLON, TRANSVERSE; COLONOSCOPY; DIVERTICULITIS, COLONIC; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL AGENTS; HUMANS; INTEGRIN ALPHA CHAINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIFAMYCINS; TREATMENT OUTCOME;

EID: 58149085792     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802321204     Document Type: Article

References (55)

1. Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975;4:3-21.
2. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11.
3. Farrell RJ, Farrell JJ, Morrin MM. Diverticular disease in the elderly. Gastroenterol Clin North Am 2001;30:475-96.
4. Almy TP, Howell DA. Diverticular disease of the colon. N Engl J Med 1980;302:324-31.
5. Simmang CL, Shires GT. Diverticular disease of the colon. In: Feld M, Sleisenger MH, Scharschmidt BF, editors. Sleisinger & Fordtran's gastrointestinal and liver disease, 6th ed. Philadelphia: WB Saunders; 1998. pp 1788-98.
6. Floch MN, Fuchs H-M. Modification of stool content by increased bran intake. J Clin Nutr 1978; 31 Suppl 1:185-9.
7. Isolauri E, Sütas Y, Kankaapää P, Arvilommi H, Salminen S. Probiotics: effect on immunità. Am J Clin Nutr 2001;73 Suppl:444-50.
8. Akira S. Toll-like receptor signaling. J Biol Chem 2003;278:38105-8.
9. Collins SM, Vallance B, Barbara G, Borgaonkar M. Putative inflammatory and immunological mechanism in functional bowel disorders. Bailleres Best Pract Res Clin Gastroenterol 1999;13:429-36.
10. Sanovic S, Lamb DP, Blennerhasset MG. Damage to the enteric nervous system in experimental colitis. Am J Pathol 1999;155:1051-7.
11. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 1997;314:779-82.
12. Isgar B, Barman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983;24:190-2.
13. Barbara G, De Giorgio R, Stanghellin V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002;51 Suppl 1:141-4.
14. Wittig BM, Zeitz M. The gut as an organ of immunology. Int J Colorectal Dis 2003;18:181-7.
15. Petruzziello L, Iacopini F, Bulajic M, Shah S, Costamagna G. Review article: uncomplicated diverticular disease of the colon. Aliment Pharmacol Ther 2006;23:1379-91.
16. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory bowel disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
17. Sadlack B, Metz H, Schorle H, Schimpl A, Feller A, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
18. Kühn R, Löhler J, Rennick D, Rajewski K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
19. Hu MC, Crowe DT, Weissman IL, Holzmann B. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing. Proc Natl Acad Sci USA 1992;89:8254-8.
20. Schweighoffer T, Tanaka Y, Tidswell M, Erle DJ, Horgan KJ, Luce GE, et al. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism. J Immunol 1993;151:717-29.
21. Farstad IN, Halstensen TS, Lien B, Kilshaw PJ, Lazarovits AI, Brandtzaeg P. Distribution of beta 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue. Immunology 1996;89:227-37.
22. Newham P, Craig SE, Seddon GN, Schofield NR, Rees A, Edwards RM, et al. Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J Biol Chem 1997;272:19429-40.
23. Lefrancois L, Parker CM, Olson S, Muller W, Wagner N, Schon MP, et al. The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. J Exp Med 1999;189:1631-8.
24. Higgins JM, Cernadas M, Tan K, Irie A, Wang J, Takada Y, et al. The role of alpha and beta chains in ligand recognition by beta 7 integrins. J Biol Chem 2000;275:25652-64.
25. Wagner N, Lohler J, Kunkel EJ, Ley K, Leung E, Krissansen G, et al. Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature 1996;382:366-70.
26. Schon MP, Arya A, Murphy EA, Adams CM, Strauch UG, Agace WW, et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol 1999;162:6641-9.
27. Parry S, Forgacs I. Intestinal infection and irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005;17:5-9.
28. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83.
29. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997;112:1714-43.
30. Gargala G, Lecleire S, Francois A, Jacquot S, Déchelotte P, Ballet JJ, et al. Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia. World J Gastroenterol 2007;13:2333-8.
31. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507.
32. Egger LA, Kidambi U, Cao J, Van Riper G, McCauley E, Mumford RA, et al. Alpha(4)beta(7)/alpha(4)beta(1) dual integrin antagonists block alpha(4)beta(7)-dependent adhesion under shear flow. J Pharmacol Exp Ther 2002;302:153-62.
33. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
34. Kieff BJ, Eckert GJ, Imperiale TF. Is diverticulosis associated with colorectal neoplasia? A cross-sectional colonoscopic study. Am J Gastroenterol 2004;99:2007-11.
35. Kohler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg Endosc 1999;13:430-6.
36. Pandolfi F, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni-Celli S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991;51:3164-70.
37. Bennett WT, Pandolfi F, Grove BH, Hawes GE, Boyle LA, Kradin RL, et al. Dominant rearrangements among human tumor-infiltrating lymphocytes. Analysis of T-cells derived from 32 patients with melanoma, lung, and renal cell carcinoma. Cancer 1992;69:2379-84.
38. Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005;100:2560-8.
39. Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999;116:310-9.
40. Sartor RB. Enteric microflora in IBD: pathogens or commensals? Inflam Bowel Dis 1997;3:230-5.
41. Harper PH, Lee ECG, Kettlewell MGW, Bennett MK, Jewell DP. Role of the fecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-84.
42. Krock A, Lindstrom B, Kjellander J, Jarnerot G, Bodin L. Relation between concentrations of metronidazole and Bacteroides spp in feces of patients with Crohn's disease and healthy individuals. J Clin Pathol 1981;34:645-50.
43. Fiocchi C. Inflammatory bowel disease; etiology and pathogenesis. Gastroenterology 1998;115:182-205.
44. Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation. In: Kirsner JB, editor. Inflammatory bowel disease, 5th ed. Philadelphia: W.B Saunders; 1999.
45. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987;28:1221-7.
46. Kamath PS, Hoepfner MT, Philips SF. Volatile fatty acids stimulate ileal peristalsis. Gastroenterology 1987;90:A1482.
47. Kamath PS, Philips SF. Initiation of motility in canine ileum by short chain fatty acids and inhibition by pharmacological agents. Gut 1988;29:941-8.
48. Uribe A, Alam M, Johansson O, Midtvedt T, Theodorsson E. Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat. Gastroenterology 1994;107:1259-69.
49. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition og intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002;68:246-56
50. Giochetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P. Review: antibiotic treatment in inflammatory bowel disease. Rifaximin, a new possible approach. Eur Rev Med Pharmacol Sci 1999;3:27-30.
51. Annacker O, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005;202:1051-61.
52. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of SCID mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997;158:2099-106.
53. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. and the Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
54. Allez M, Brimnes J, Dotan I, Mayer L. Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 2002;123:1516-26.
55. Oshitani N, Watanabe K, Maeda K, Fujiwara Y, Higuchi K, Matsumoto T, et al. Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease. Int J Mol Med 2003;12:715-9.